'To Be or Not to Be,' That's the Question for The National Action Plan on Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 4
Volume 6
Issue 4

WASHINGTON--The steering committee of the National Action Plan on Breast Cancer (NAPBC) finds itself confronting its future--whether it should have one. Should the group set a time to end the innovative program, or should it continue?

WASHINGTON--The steering committee of the National Action Plan on BreastCancer (NAPBC) finds itself confronting its future--whether it should haveone. Should the group set a time to end the innovative program, or shouldit continue?

The issue, spawned by an earlier steering committee decision [see OncologyNews International, December 1996], arose again during a meeting with Healthand Human Services Secretary Donna E. Shalala, PhD.

Last November, the committee voted to return to the National CancerInstitute all but $750,000 of the $14.75 million allotted to the NAPBC(and to other cross-cutting breast cancer activities) by Congress for thecurrent fiscal year.

Most members believe the program should serve as a catalyst, identifyingareas of need in breast cancer research, care, and education, and thenworking with appropriate agencies and organizations to get these issuesgreater funding and attention. They do not want the NAPBC to fund researchdirectly.

Last November, the steering committee asked that the $14 million goto the National Cancer Institute for research. The committee, consistingof representatives from inside and outside the federal government, is uniquein the federal system. It believes it has the power to decide what theNAPBC will do, not just serve as an advisory board.

'A New Concept'

At their February meeting, committee members sought to clarify the powerissue with Secretary Shalala. And at one point, Susan M. Love, MD, adjunctassociate professor of surgery, UCLA, told the HHS Secretary: "Wereally never intended to go on forever and become another bureaucracy."Dr. Love suggested that the group should think about setting a time towind up its efforts and go out of business.

"That's a new concept for those of us who have been in government,"Secretary Shalala jokingly replied. The Secretary asked the committee togive her its thoughts by the end of the day about whether the NAPBC shouldcease. The committee chose, however, to give the matter to one of its internalworking groups for greater consideration.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.